NL-OMON27469
Recruiting
Not Applicable
A phase I study assessing the safety and performance of VB5-845D-800CW, an anti-Epcam fluorescent agent, for the intraoperative detection of gastrointestinal cancer
eiden University Medical Center (LUMC)0 sites34 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- eiden University Medical Center (LUMC)
- Enrollment
- 34
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
.A.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Part A (healthy volunteers)
- •A maximum of sixteen (16\) healthy volunteers will take part in this study.
Exclusion Criteria
- •Part A (healthy volunteers)
- •A maximum of sixteen (16\) healthy volunteers will take part in this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A phase I study assessing the safety and performance of VB5-845D-800CW, an anti-Epcam fluorescent agent, for the intraoperative detection of gastrointestinal canceresophageal/gastric- or colorectal cancer10017990NL-OMON48830eids Universitair Medisch Centrum34
Active, not recruiting
Phase 1
A Phase I/II study to evaluate Trappsol Cyclo (hydroxypropyl-ß-cyclodextrin) in patients with Niemann-Pick disease type C (NPC-1) to assess what the drug does to the body, and what the body does to the drug, and the side effects and benefits experienced by patientsiemann-Pick disease type CMedDRA version: 20.0Level: PTClassification code 10029403Term: Niemann-Pick diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2015-005761-23-SECyclo Therapeutics, Inc.11
Active, not recruiting
Phase 1
A Phase I/II study to evaluate Trappsol Cyclo (hydroxypropyl-ß-cyclodextrin) in patients with Niemann-Pick disease type C (NPC-1) to assess what the drug does to the body, and what the body does to the drug, and the side effects and benefits experienced by patientsiemann-Pick disease type CMedDRA version: 20.0 Level: PT Classification code 10029403 Term: Niemann-Pick disease System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2015-005761-23-GBCTD Holdings, Inc.12
Active, not recruiting
Phase 1
A Phase I/II study to evaluate Trappsol Cyclo (hydroxypropyl-ß-cyclodextrin) in patients with Niemann-Pick disease type C (NPC-1) to assess what the drug does to the body, and what the body does to the drug, and the side effects and benefits experienced by patientsiemann-Pick disease type CMedDRA version: 20.0Level: PTClassification code 10029403Term: Niemann-Pick diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2015-005761-23-ITCTD HOLDINGS, INC.12
Active, not recruiting
Phase 1
A study evaluating the safety and activity of a new drug - pegylated recombinant hyman arginase (BCT-100) in cancers in children and young people that have come back (relapsed) or have not responded to treatment (refractory).Relpased/refractory paeditaric cancers:LeukaemiasSarcomaNeuroblastomaHigh grade glioma (brain cancers)MedDRA version: 21.0Level: PTClassification code 10000830Term: Acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10039494Term: Sarcoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-002762-44-IEniversity of Birmingham64